Pneumococcal infection
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infections with bacteria of the species streptococcus pneumoniae.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pneumococcal infection
- Therapeutic area
- Infectious Disease
- pneumococcal infection
- Streptococcus pneumoniae caused disease or disorder
- Streptococcus pneumoniae disease or disorder
- Streptococcus pneumoniae infectious disease
- pneumococcal infection
- Streptococcus pneumoniae infection
- Streptococcus pneumoniae infections
- infection, Streptococcus pneumoniae
- infection, pneumococcal
- infections, Streptococcus pneumoniae
- infections, pneumococcal
- pneumoniae infection, Streptococcus
- pneumoniae infections, Streptococcus
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0005114
- Parent condition
- MONDO:0021680
Related records
Broader conditions (8)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Gram-positive bacterial infections
- Human disease
- Infectious disease
- Streptococcal infection
Narrower conditions (3)
- Pneumococcal meningitis
- Streptococcal pneumonia
- Streptococcus pneumoniae discitis
Trials (299)
- 13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study
- 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
- 9-valent CRM 197 Pneumococcal
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
- A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
- A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
- A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
- A Controlled Human Pneumococcal Infection Model (PIM) Study
- A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
- A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Approved drugs (4)
- Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae CRM197
- Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid
- Streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein D
- Streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid
Drugs in development (7)
- Elasomeran Phase 3
- Influenza virus vaccine Phase 3
- KP-1461 Phase 2
- Penicillin G Phase 3
- Pertussis vaccine Phase 1
- Rituximab Phase 2
- Sodium chloride Phase 3